Anti-tumour therapeutic efficacy of OX40L in murine tumour model (Q40524659)

21 September 2017

Anti-tumour therapeutic efficacy of OX40L in murine tumour model (English)

1 reference

21 September 2017

Selman A Ali

1

1 reference

21 September 2017

Murrium Ahmad

2

1 reference

21 September 2017

June Lynam

3

1 reference

21 September 2017

Cornelia S McLean

4

1 reference

21 September 2017

Claire Entwisle

5

1 reference

21 September 2017

Peter Loudon

6

1 reference

21 September 2017

Esther Choolun

7

1 reference

21 September 2017

Stephanie E B McArdle

8

1 reference

21 September 2017

Geng Li

9

1 reference

21 September 2017

Shahid Mian

10

1 reference

21 September 2017

Robert C Rees

11

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

21 September 2017

1 reference

21 September 2017

22

1 reference

21 September 2017

3585-3594

1 reference

21 September 2017

27-28

1 reference

The two-signal model of lymphocyte activation twenty-one years later

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Costimulation of T-cell-mediated tumor immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Selective induction of high avidity CTL by altering the balance of signals from APC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Signaling through OX40 (CD134) breaks peripheral T-cell tolerance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Engagement of the OX-40 receptor in vivo enhances antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Expression in COS cells of a mouse-human chimaeric B72.3 antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.041

10.1016/J.VACCINE.2004.03.041

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference